Profesionales de la salud   /     /     /     /  

Sequential Couplets of Cisplatin/Topotecan and Cisplatin/Paclitaxel as First-Line Therapy in Advanced Epithelial Ovarian Cancer

University of Pennsylvania Cancer Center
Ultima Vez Modificado: 16 de mayo del 1999

Dr. P. Hoskins presented a Phase II trial of sequential couplets of cisplatin (DDP) and topotecan (TOP) and cisplatin and paclitaxel (T) as first-line therapy for advanced epithelial ovarian cancer on behalf of the National Cancer Institute of Canada. The dosage used were as follows:

DDP/TOP cycles: DDP 50 mg/m2 and TOP 0.75 mg/m2

DDP/T cycles: DDP 75 mg/m2 and T 135 mg/m2 IV infusion over 24 hours

Interval debulking was allowed.

Dr. Hoskins reported that:

• Dose reduction was needed in 13% of DDP/TOP cycles

• Dose delays were incurred in 9% of DDP/TOP cycles

• A response rate of 85%

• Myelotoxcity of this couplet regimen is high but does not prevent delivery.

• The response rate is encouraging being that these were predominately suboptimal patients.

• Cisplatin was used instead of carboplatin

• Marked reduction in topotecan dosing

• Treatment delay was common

• Substantial toxicity